Thomas Boulet

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Sara A. Hurvitz, Miguel Martín, Kyung Hae Jung et al. · Journal of Clinical Oncology · 2019 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Eleftherios P. Mamounas, Michael Untch, Max S. Mano et al. · Annals of Oncology · 2021 · 123 citations · Full text

Medicine, Oncology, Pharmacology +17

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang et al. · New England Journal of Medicine · 2025 · 115 citations · Full text

Medicine, Oncology, Pharmacology +14

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

Rosa Conforti, Thomas Boulet, Gorana Tomasic et al. · Annals of Oncology · 2007 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17

Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers

Stefan Michiels, Patrick Danoy, P Dessen et al. · Carcinogenesis · 2007 · 71 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15